Results 161 to 170 of about 52,918 (218)

mRNA Lipid Nanoparticles for Cell Engineering in Vivo and in Vitro: Current Applications and Future Directions

MedComm, Volume 7, Issue 5, May 2026.
Schematic diagram of mRNA‐lipid nanoparticles (mRNA‐LNP) and its functional mechanisms, applications, and challenges in cell engineering. This figure details the structural composition of mRNA‐LNPs and the delivery strategy, highlighting three core challenges.
Lina Li, Menglan Wang, Xiuhan Ye, Zhiyan Liu, Yijing Duan, Xiaoming Chen, Yue Ouyang, Qibiao Wu, Mengjuan Sun, Tian Xie   +9 more
wiley   +1 more source

Neurotransmitter Systems in Alzheimer's Disease. [PDF]

Curr Issues Mol Biol
Ramírez-Expósito MJ, Cueto-Ureña C, Martínez-Martos JM.   +2 more
europepmc   +1 more source

Exploring Linalool‐Based Phytotherapy for Excitatory/Inhibitory Imbalance in Alzheimer's Disease: A Review of Lavender and Cannabis Therapeutic Effects on Sleep, Seizures, and Cognition

Phytotherapy Research, Volume 40, Issue 5, Page 2604-2631, May 2026.
Schematic overview of the proposed neuromodulatory actions of linalool in Alzheimer's disease. Through multi‐target effects on oxidative stress, amyloid aggregation, GABAergic and glutamatergic signaling, linalool may restore excitatory/inhibitory balance.
Ilaria Piccialli, Giovanni Roviello, Giorgia Magliocca, Emilia Esposito, Anna Pannaccione   +4 more
wiley   +1 more source

Modelling Neural Disorders with the <i>D. melanogaster</i> Larval Peripheral and Adult Dopaminergic Systems. [PDF]

Biomolecules
Tendero-Lopez D, Dominguez M, Aguilar-Aragon M.   +2 more
europepmc   +1 more source

Enteric Nervous System Damage by Food Contaminants: A Pathway to Neurodegeneration?

Comprehensive Reviews in Food Science and Food Safety, Volume 25, Issue 3, May 2026.
ABSTRACT The enteric nervous system (ENS), a key component of the gut–brain axis, has emerged as a critical player in the pathogenesis of Parkinson's disease (PD). It is the first neural system exposed to food contaminants (FCs)—a diverse group of ubiquitous toxic compounds fortuitously present in food derived from production, processing, storage, or ...
Helena Ramos, Ana Margarida Araújo, Isabel M. P. L. V. O. Ferreira, Miguel A. Faria   +3 more
wiley   +1 more source

From pathogenesis to treatment: the emerging role of ferroptosis in Parkinson's disease. [PDF]

Front Immunol
Tu R, Han Z, Zhang H, Jia X, Sun T, Liu H, Li J, Tang M, Wang S.   +8 more
europepmc   +1 more source

Profiling of HCAR1 signalling reveals Gαi/o and Gαs activation without β‐arrestin recruitment and the discovery of an allosteric agonist

British Journal of Pharmacology, Volume 183, Issue 10, Page 2219-2235, May 2026.
Abstract Background and Purpose Lactate, historically viewed as a metabolic by‐product, has emerged as a signalling molecule via the G protein–coupled receptor Hydroxycarboxylic Acid Receptor 1 (HCAR1). The receptor is primarily expressed in adipocytes but also found in various other tissues.
Simon Lind, Shane C. Wright, Emilia Gvozdenovic, Kristina Nilsson, Kenneth L. Granberg, Michel Bouvier, Linda C. Johansson   +6 more
wiley   +1 more source

Gangliosides in molecular interactions and cell regulation. [PDF]

J Biol Chem
Mlinac-Jerkovic K, Heffer M, Schnaar RL.
europepmc   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Alpha-methyl-para-tyrosine and amphetamine ameliorate hyperactivity in a novel mouse model of dopamine transporter deficiency syndrome. [PDF]

EMBO Mol Med
Russo EE, Rezayof A, Wallace C, Williams EQ, Beerepoot P, Milenkovic M, Novalen M, Blundell A, Lipina TV, Locke J, Christian R, Finnie PSB, Edgar LJ, Tyndale RF, Watkins-Chow D, Ramsey AJ, Jones SR, Salahpour A.   +17 more
europepmc   +1 more source